Literature DB >> 16416038

Cardiovascular risk in Cushing's syndrome.

Giorgio Arnaldi1, Tatiana Mancini, Barbara Polenta, Marco Boscaro.   

Abstract

Chronic cortisol hypersecretion causes central obesity, hypertension, insulin resistance, dyslipidemia, protrombotic state, manifestations which form a metabolic syndrome in all patients with Cushing's syndrome. These associated abnormalities determine an increased cardiovascular risk not only during the active phase of the disease but also long after the "biomedical remission". Clinical management of these patients should be particularly careful in identifying global cardiovascular risk. Considering that remission from hypercortisolism is often difficult to achieve care and control of all cardiovascular risk factors should be one of the primary goals during the follow up of these patients. Extending the indications of the recent consensus on Cushing's syndrome, we suggest to carry out an OGTT to avoid underestimation of diabetes mellitus, an echocardiography and Doppler ultrasonography of the epiaortic vessels in all patients at diagnosis and during follow-up.

Entities:  

Mesh:

Year:  2004        PMID: 16416038     DOI: 10.1007/s11102-005-1172-7

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  16 in total

1.  1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee.

Authors: 
Journal:  J Hypertens       Date:  1999-02       Impact factor: 4.844

Review 2.  Diagnosis and complications of Cushing's syndrome: a consensus statement.

Authors:  G Arnaldi; A Angeli; A B Atkinson; X Bertagna; F Cavagnini; G P Chrousos; G A Fava; J W Findling; R C Gaillard; A B Grossman; B Kola; A Lacroix; T Mancini; F Mantero; J Newell-Price; L K Nieman; N Sonino; M L Vance; A Giustina; M Boscaro
Journal:  J Clin Endocrinol Metab       Date:  2003-12       Impact factor: 5.958

3.  Gender-related differences in the presentation and course of Cushing's disease.

Authors:  Francesca Pecori Giraldi; Mirella Moro; Francesco Cavagnini
Journal:  J Clin Endocrinol Metab       Date:  2003-04       Impact factor: 5.958

Review 4.  Glucocorticoids and insulin resistance: old hormones, new targets.

Authors:  R C Andrews; B R Walker
Journal:  Clin Sci (Lond)       Date:  1999-05       Impact factor: 6.124

5.  Blunted vascular and renal effects of exogenous atrial natriuretic peptide in patients with cushing's disease.

Authors:  C Sala; B Ambrosi; A Morganti
Journal:  J Clin Endocrinol Metab       Date:  2001-05       Impact factor: 5.958

6.  Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing's syndrome.

Authors:  Marco Boscaro; Nicoletta Sonino; Alessandro Scarda; Luisa Barzon; Francesco Fallo; Maria T Sartori; Giovanni M Patrassi; Antonio Girolami
Journal:  J Clin Endocrinol Metab       Date:  2002-08       Impact factor: 5.958

7.  Morbidity and mortality in Cushing's disease: an epidemiological approach.

Authors:  J Etxabe; J A Vazquez
Journal:  Clin Endocrinol (Oxf)       Date:  1994-04       Impact factor: 3.478

8.  Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission.

Authors:  Antongiulio Faggiano; Rosario Pivonello; Stefano Spiezia; Maria Cristina De Martino; Mariagiovanna Filippella; Carolina Di Somma; Gaetano Lombardi; Annamaria Colao
Journal:  J Clin Endocrinol Metab       Date:  2003-06       Impact factor: 5.958

9.  Elevated plasma endothelin as an additional cardiovascular risk factor in patients with Cushing's syndrome.

Authors:  G Kirilov; A Tomova; L Dakovska; Ph Kumanov; A Shinkov; A S Alexandrov
Journal:  Eur J Endocrinol       Date:  2003-12       Impact factor: 6.664

10.  Hyperhomocysteinemia in patients with Cushing's syndrome.

Authors:  Massimo Terzolo; Barbara Allasino; Sandra Bosio; Elena Brusa; Fulvia Daffara; Massimo Ventura; Emiliano Aroasio; Gianna Sacchetto; Giuseppe Reimondo; Alberto Angeli; Clara Camaschella
Journal:  J Clin Endocrinol Metab       Date:  2004-08       Impact factor: 5.958

View more
  23 in total

Review 1.  Italian Society for the Study of Diabetes (SID)/Italian Endocrinological Society (SIE) guidelines on the treatment of hyperglycemia in Cushing's syndrome and acromegaly.

Authors:  M G Baroni; F Giorgino; V Pezzino; C Scaroni; A Avogaro
Journal:  J Endocrinol Invest       Date:  2015-12-30       Impact factor: 4.256

2.  Intracerebral hemorrhage revealing a Cushing's disease.

Authors:  Héloïse Chauveau; Nadia Berhoune; Claire Sharon; Emmanuel Jouanneau; Norbert Nighoghossian
Journal:  Am J Cardiovasc Dis       Date:  2015-10-12

Review 3.  Pros and cons of screening for occult Cushing syndrome.

Authors:  Antoine Tabarin; Paul Perez
Journal:  Nat Rev Endocrinol       Date:  2011-03-22       Impact factor: 43.330

Review 4.  Minireview: new molecular mediators of glucocorticoid receptor activity in metabolic tissues.

Authors:  Rucha Patel; Jasmine Williams-Dautovich; Carolyn L Cummins
Journal:  Mol Endocrinol       Date:  2014-04-25

Review 5.  Glucocorticoids and the regulation of growth hormone secretion.

Authors:  Gherardo Mazziotti; Andrea Giustina
Journal:  Nat Rev Endocrinol       Date:  2013-02-05       Impact factor: 43.330

6.  Blood pressure in pediatric patients with Cushing syndrome.

Authors:  Maya B Lodish; Ninet Sinaii; Nicholas Patronas; Dalia L Batista; Meg Keil; Jonelle Samuel; Jason Moran; Somya Verma; Jadranka Popovic; Constantine A Stratakis
Journal:  J Clin Endocrinol Metab       Date:  2009-03-17       Impact factor: 5.958

7.  Biochemical markers for cardiovascular risk following treatment in endogenous Cushing's syndrome.

Authors:  C Kristo; T Ueland; K Godang; P Aukrust; J Bollerslev
Journal:  J Endocrinol Invest       Date:  2008-05       Impact factor: 4.256

8.  Medical treatment of Cushing's disease: Overview and recent findings.

Authors:  Stephanie Smooke Praw; Anthony P Heaney
Journal:  Int J Gen Med       Date:  2009-12-29

9.  Impact of sleep and its disturbances on hypothalamo-pituitary-adrenal axis activity.

Authors:  Marcella Balbo; Rachel Leproult; Eve Van Cauter
Journal:  Int J Endocrinol       Date:  2010-06-09       Impact factor: 3.257

10.  Treatment of Cushing disease: overview and recent findings.

Authors:  Tatiana Mancini; Teresa Porcelli; Andrea Giustina
Journal:  Ther Clin Risk Manag       Date:  2010-10-21       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.